Opus Genetics Gains Momentum In Inherited Retinal Disease Treatments

Inherited retinal diseases can progress quickly, often leaving patients with few or no treatment options. Opus Genetics is advancing several gene therapy programs aimed at restoring visual function in conditions driven by rare genetic mutations, including Leber congenital amaurosis type 5 and BEST1-related retinal diseases. The company’s OPGx-LCA5 program has been accepted into the FDA’s Rare Disease Evidence Principles program, a step that could support a more predictable development path for therapies serving very small patient populations. Early clinical findings presented at ARVO also point to encouraging tolerability and biological activity across multiple programs, including evidence of restored cone-mediated function in pediatric LCA5 patients with severe baseline vision loss.

Learn how these milestones may shape the future of gene therapy for inherited blinding diseases.